Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean

IlDong Pharmaceutical

Status and phase

Completed

Phase 3

Conditions

Acute Migraine

Treatments

Drug: Lasmiditan 100mg

Drug: Lasmiditan 50mg

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT04218162

ID-LAS-301

Details and patient eligibility

About

A randomized, double-blind, placebo-controlled parallel group study to evaluate efficacy and safety of lasmiditan tablet compared to Placebo in the acute treatment of Migraine

Enrollment

294 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Able and willing to give written informed consent.
Male or female, aged 18 years or above.
Participants with migraine with or without aura fulfilling the International Headache Society (IHS) diagnostic criteria 1.1 and 1.2.1 (International Headache Classification (ICHD-3).
History of disabling migraine for at least 1 year.
Migraine Disability Association (MIDAS) score ≥11.
Migraine onset before the age of 50 years.
History of 3 - 8 migraine attacks per month (< 15 headache days per month).
Females of child-bearing potential must be using or willing to use a highly effective form of contraception (e.g. combined oral contraceptive, intrauterine device (IUD), abstinence or vasectomized partner).
Able and willing to complete an electronic diary to record details of the migraine attack treated with study drug.

Exclusion criteria

Any medical condition or clinical laboratory test which in the judgment of the Investigator makes the participant unsuitable for the study.
Pregnant or breast-feeding women.
Known hypersensitivity to lasmiditan or to any excipient of lasmiditan oral tablets, or any sensitivity to lasmiditan.
History or evidence of hemorrhagic stroke, epilepsy or any other condition placing the participant at increased risk of seizures.
History of recurrent dizziness and/or vertigo including benign paroxysmal positional vertigo (BPPV), Meniere's disease, vestibular migraine, and other vestibular disorders.
History of diabetes mellitus with complications (diabetic retinopathy, nephropathy or neuropathy).
History within the previous three years or current evidence of abuse of any drug, prescription or illicit, or alcohol.
History of orthostatic hypotension with syncope.
Significant renal or hepatic impairment.
Participant is at imminent risk of suicide (positive response to question 4 or 5) on the Columbia-Suicide Severity Rating Scale (C-SSRS) or had a suicide attempt within six months prior to screening.
Participation in any clinical trial of an experimental drug or device in the previous 30 days.
Known Hepatitis B or C or human immunodeficiency virus(HIV) infection. History, within past 12 months, of chronic migraine or other forms of primary or secondary chronic headache disorder (e.g. hemicranias continua, medication overuse headache) where headache frequency is ≥15 headache days per month.
Use of more than 3 doses per month of either opiates or barbiturates.
Initiation of or a change in concomitant medication to reduce the frequency of migraine episodes within three (3) months prior to Screening/Visit 1.